VPM1002 was evaluated in a large phase 3 study in household contacts of TB patients, assessing safety, immunogenicity, and efficacy across pulmonary and extrapulmonary tuberculosis outcomes.
Here is the link to the full publication.
VPM1002 was evaluated in a large phase 3 study in household contacts of TB patients, assessing safety, immunogenicity, and efficacy across pulmonary and extrapulmonary tuberculosis outcomes.
Here is the link to the full publication.